Active

PROGRESS PHARMA

Switched

BE0536258560

Rechtspersoon Public limited company 1 establishment

Roekendreef 14, 2350 Vosselaar Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Active for

13 year, 2 months

Financials

Financial year 2025

Worth noting

  • A loss two years in a row.

Gross margin

€ -4,893

▼ 108% vs 2024

Profit

Caution

€ -5,479

▼ 88% vs 2024

Debts

Low

€ 2,797

▲ 95% vs 2024

PROGRESS PHARMA from Vosselaar, company number BE0536258560, closed financial year 2025 with a result of € -5,479 after tax. For that financial year PROGRESS PHARMA recorded a gross margin of € -4,893 and equity of € 47,137. Compared with financial year 2024, the result moved from € -2,921 to € -5,479. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.

What happened at PROGRESS PHARMA?

What happened at PROGRESS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: loss of € 5,479. Source: NBB ↗
  • New establishment in Vosselaar. KBO
  • Start of the company according to the CBE. KBO

In short

From € 2,202 loss in 2021 to € 5,479 loss in 2025.

A new publication or filing at PROGRESS PHARMA? We notify you, reason included.

Follow PROGRESS PHARMA

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Luc Lammens
SALVEGEN HEALTHCARE BV
+1
PROGRESS PHARMA

Behind PROGRESS PHARMA are Luc Lammens, SALVEGEN HEALTHCARE BV, R&S CONSULTING BV, SIMBIOSIS.LIFE BV and CONCORDE CONSULTING BV. It owns 100% of Etherna immunotherapies itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Luc Lammens

Director

Also active at: Kronenburg, INNOFOCUS, Innofocus Services +1 more

SALVEGEN HEALTHCARE BV

Managing director · represented by Emilius VAN DONGEN

R&S CONSULTING BV

Chairman of the board · represented by Dirk Reyn

Also active at: BIOQUBE VENTURES

SIMBIOSIS.LIFE BV

Director · represented by Marina COOLS

CONCORDE CONSULTING BV

Director · represented by Dirk VAN BROEKHOVEN

Establishments

Establishment units

Physical locations of this company

Registered office

Roekendreef 14

2350 Vosselaar

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

Details

Company number
0536.258.560
VAT number
BE 0536.258.560
Registered office
Roekendreef 14, 2350 Vosselaar
Names & denominations
PROGRESS PHARMA
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
27 June 2013
Peppol
Active · Active since 4 Jun 2025
Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige zakelijke dienstverlening, neg

Frequently asked questions

What is the enterprise number of PROGRESS PHARMA?
The enterprise number of PROGRESS PHARMA is BE0536258560.
What is the address of PROGRESS PHARMA?
The registered office of PROGRESS PHARMA is located at Roekendreef 14, 2350 Vosselaar.
When was PROGRESS PHARMA founded?
PROGRESS PHARMA was founded on 27 June 2013.
What is the main activity of PROGRESS PHARMA?
The main activity of PROGRESS PHARMA is "Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied" (NACE code 72109).
Does PROGRESS PHARMA have a website?
No website is currently known for PROGRESS PHARMA.
How much profit did PROGRESS PHARMA make in 2025?
PROGRESS PHARMA recorded a loss after taxes of € 5,479 in financial year 2025.
What is the revenue of PROGRESS PHARMA?
As a small company, PROGRESS PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -4,893.
Where can I find the annual accounts of PROGRESS PHARMA?
PROGRESS PHARMA files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of PROGRESS PHARMA?
According to the 2025 annual accounts, the directors of PROGRESS PHARMA are: Luc Lammens, SALVEGEN HEALTHCARE BV, R&S CONSULTING BV, SIMBIOSIS.LIFE BV, CONCORDE CONSULTING BV.
Who owns PROGRESS PHARMA?
Behind PROGRESS PHARMA are Luc Lammens, SALVEGEN HEALTHCARE BV, R&S CONSULTING BV, SIMBIOSIS.LIFE BV and CONCORDE CONSULTING BV. It owns 100% of Etherna immunotherapies itself.